UY35962A - Formulaciones de liberación modificada de pridopidina - Google Patents
Formulaciones de liberación modificada de pridopidinaInfo
- Publication number
- UY35962A UY35962A UY0001035962A UY35962A UY35962A UY 35962 A UY35962 A UY 35962A UY 0001035962 A UY0001035962 A UY 0001035962A UY 35962 A UY35962 A UY 35962A UY 35962 A UY35962 A UY 35962A
- Authority
- UY
- Uruguay
- Prior art keywords
- pridopidine
- modified release
- dosage form
- solid oral
- release formulations
- Prior art date
Links
- YGKUEOZJFIXDGI-UHFFFAOYSA-N pridopidine Chemical compound C1CN(CCC)CCC1C1=CC=CC(S(C)(=O)=O)=C1 YGKUEOZJFIXDGI-UHFFFAOYSA-N 0.000 title abstract 3
- 229950003764 pridopidine Drugs 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title 1
- 239000007787 solid Substances 0.000 abstract 3
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 abstract 2
- 239000006186 oral dosage form Substances 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229960003638 dopamine Drugs 0.000 abstract 1
- 239000002552 dosage form Substances 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2068—Compounds of unknown constitution, e.g. material from plants or animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Inorganic Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Botany (AREA)
- Zoology (AREA)
- Psychology (AREA)
- Anesthesiology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Oil, Petroleum & Natural Gas (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461930358P | 2014-01-22 | 2014-01-22 | |
| US201462050626P | 2014-09-15 | 2014-09-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY35962A true UY35962A (es) | 2015-08-31 |
Family
ID=53543863
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY0001035962A UY35962A (es) | 2014-01-22 | 2015-01-22 | Formulaciones de liberación modificada de pridopidina |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US20150202302A1 (OSRAM) |
| EP (2) | EP4049657A1 (OSRAM) |
| JP (2) | JP6949487B2 (OSRAM) |
| KR (1) | KR102479759B1 (OSRAM) |
| CN (1) | CN106170287A (OSRAM) |
| AU (1) | AU2015209411A1 (OSRAM) |
| CA (1) | CA2937243C (OSRAM) |
| CL (1) | CL2016001874A1 (OSRAM) |
| DK (1) | DK3096759T3 (OSRAM) |
| EA (1) | EA201691454A1 (OSRAM) |
| ES (1) | ES2911800T3 (OSRAM) |
| HU (1) | HUE058288T2 (OSRAM) |
| IL (2) | IL246598B (OSRAM) |
| MX (1) | MX377576B (OSRAM) |
| PE (1) | PE20161220A1 (OSRAM) |
| PL (1) | PL3096759T3 (OSRAM) |
| TW (1) | TW201605446A (OSRAM) |
| UA (1) | UA122053C2 (OSRAM) |
| UY (1) | UY35962A (OSRAM) |
| WO (1) | WO2015112601A1 (OSRAM) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE46117E1 (en) | 1999-12-22 | 2016-08-23 | Teva Pharmaceuticals International Gmbh | Modulators of dopamine neurotransmission |
| EA201390332A1 (ru) | 2010-09-03 | 2013-08-30 | Ивакс Интернэшнл Гмбх | Дейтерированные аналоги придопидина, применимые в качестве допаминергических стабилизаторов |
| MX347209B (es) | 2011-12-08 | 2017-04-19 | Teva Pharmaceuticals Int Gmbh | La sal de bromhidrato de pridopidina. |
| WO2014205229A1 (en) | 2013-06-21 | 2014-12-24 | IVAX International GmbH | Use of high dose pridopidine for treating huntington's disease |
| US11090297B2 (en) | 2013-06-21 | 2021-08-17 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating huntington's disease |
| HUE058288T2 (hu) | 2014-01-22 | 2022-07-28 | Prilenia Neurotherapeutics Ltd | Pridopidin módosított hatóanyag-leadású készítményei |
| TW201613859A (en) | 2014-06-30 | 2016-04-16 | Teva Pharma | Analogs of PRIDOPIDINE, their preparation and use |
| EP3236964A4 (en) | 2014-12-22 | 2018-09-19 | Teva Pharmaceuticals International GmbH | L-tartrate salt of pridopidine |
| EP3590512A1 (en) | 2015-02-25 | 2020-01-08 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine to treat epilepsy |
| US11471449B2 (en) | 2015-02-25 | 2022-10-18 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine to improve cognitive function and for treating Alzheimer's disease |
| AR105434A1 (es) | 2015-07-22 | 2017-10-04 | Teva Pharmaceuticals Int Gmbh | Proceso para preparar pridopidina |
| CA2993183A1 (en) * | 2015-07-22 | 2017-01-26 | Teva Pharmaceuticals International Gmbh | Pridopidine base formulations and their use |
| PL3419622T3 (pl) | 2016-02-24 | 2024-07-08 | Prilenia Neurotherapeutics Ltd. | Leczenie neurodegeneracyjnej choroby oczu przy użyciu pridopidyny |
| BR112019003731A2 (pt) * | 2016-08-24 | 2019-07-16 | Prilenia Therapeutics Dev Ltd | aplicação de pridopidina para tratamento de distonias |
| JP6912574B2 (ja) | 2016-08-24 | 2021-08-04 | プリレニア ニューロセラピューティクス リミテッド | 機能低下を治療するためのプリドピジンの使用 |
| ES2986807T3 (es) * | 2016-09-16 | 2024-11-12 | Prilenia Neurotherapeutics Ltd | Pridopidina para su uso en el tratamiento del síndrome de Rett |
| US12102627B2 (en) | 2016-09-16 | 2024-10-01 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine for treating rett syndrome |
| EP3570940B1 (en) | 2017-01-20 | 2023-12-13 | Prilenia Neurotherapeutics Ltd. | Pridopidine for use in the treatment of fragile x syndrome |
| EA202090510A1 (ru) | 2017-08-14 | 2020-06-08 | Приления Ньюротерапьютикс Лтд. | Способ лечения бокового амиотрофического склероза придопидином |
| WO2019046568A1 (en) | 2017-08-30 | 2019-03-07 | Teva Pharmaceuticals International Gmbh | DOSAGE FORMS WITH HIGH CONCENTRATION OF PRIDOPIDINE |
| MX383462B (es) | 2017-09-08 | 2025-03-14 | Prilenia Neurotherapeutics Ltd | Pridopidina para el tratamiento de las discinesias inducidas por fármacos |
| US12036213B2 (en) | 2017-09-08 | 2024-07-16 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating drug induced dyskinesias |
| KR20200056071A (ko) | 2018-11-14 | 2020-05-22 | 한화토탈 주식회사 | 내열성, 강성 및 용융 강도가 우수한 폴리올레핀 수지 조성물 |
| US12357624B2 (en) | 2019-02-04 | 2025-07-15 | Prilenia Neurotherapeutics Ltd. | Low dose pridopidine for Parkinson's Disease and other diseases associated with parkinsonism |
| WO2024258929A1 (en) * | 2023-06-12 | 2024-12-19 | Unravel Biosciences, Inc. | Methods for treating diseases associated with taf1 loss of function |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4020983B2 (ja) * | 1995-07-07 | 2007-12-12 | 帝國製薬株式会社 | 持続性製剤およびその製法 |
| SE9904724D0 (sv) | 1999-12-22 | 1999-12-22 | Carlsson A Research Ab | New modulators of dopamine neurotransmission I |
| CN1193754C (zh) | 2000-03-21 | 2005-03-23 | 日本新药株式会社 | 释放控制型口服制剂 |
| AR030557A1 (es) * | 2000-04-14 | 2003-08-27 | Jagotec Ag | Una tableta en multicapa de liberacion controlada y metodo de tratamiento |
| GB0125088D0 (en) | 2001-10-18 | 2001-12-12 | Smithkline Beecham Cork Ltd | New use |
| AR046811A1 (es) * | 2003-09-02 | 2005-12-28 | Imran Ahmed | Formas de dosificacion oral de ziprasidona de liberacion sostenida |
| AU2005293754B2 (en) | 2004-10-13 | 2011-07-21 | Teva Pharmaceuticals International Gmbh | Process for the synthesis of 4-(3-methanesulfonylphenyl)-1-N-propyl-piperidine |
| US20110206782A1 (en) * | 2010-02-24 | 2011-08-25 | Auspex Pharmaceuticals, Inc. | Piperidine modulators of dopamine receptor |
| MX347209B (es) * | 2011-12-08 | 2017-04-19 | Teva Pharmaceuticals Int Gmbh | La sal de bromhidrato de pridopidina. |
| EA027748B1 (ru) | 2012-04-04 | 2017-08-31 | Тева Фармасьютикалз Интернэшнл Гмбх | Применение придопидина в комбинации с тетрабеназином для лечения двигательных нарушений и ожирения |
| WO2014205229A1 (en) * | 2013-06-21 | 2014-12-24 | IVAX International GmbH | Use of high dose pridopidine for treating huntington's disease |
| HUE058288T2 (hu) | 2014-01-22 | 2022-07-28 | Prilenia Neurotherapeutics Ltd | Pridopidin módosított hatóanyag-leadású készítményei |
-
2015
- 2015-01-21 HU HUE15740303A patent/HUE058288T2/hu unknown
- 2015-01-21 UA UAA201608936A patent/UA122053C2/uk unknown
- 2015-01-21 DK DK15740303.1T patent/DK3096759T3/da active
- 2015-01-21 KR KR1020167022884A patent/KR102479759B1/ko active Active
- 2015-01-21 PL PL15740303T patent/PL3096759T3/pl unknown
- 2015-01-21 WO PCT/US2015/012248 patent/WO2015112601A1/en not_active Ceased
- 2015-01-21 ES ES15740303T patent/ES2911800T3/es active Active
- 2015-01-21 CA CA2937243A patent/CA2937243C/en active Active
- 2015-01-21 MX MX2016009427A patent/MX377576B/es active IP Right Grant
- 2015-01-21 AU AU2015209411A patent/AU2015209411A1/en not_active Abandoned
- 2015-01-21 PE PE2016001263A patent/PE20161220A1/es not_active Application Discontinuation
- 2015-01-21 US US14/601,920 patent/US20150202302A1/en not_active Abandoned
- 2015-01-21 EP EP22163271.4A patent/EP4049657A1/en not_active Withdrawn
- 2015-01-21 EA EA201691454A patent/EA201691454A1/ru unknown
- 2015-01-21 JP JP2016547847A patent/JP6949487B2/ja active Active
- 2015-01-21 EP EP15740303.1A patent/EP3096759B1/en active Active
- 2015-01-21 CN CN201580005659.9A patent/CN106170287A/zh active Pending
- 2015-01-22 UY UY0001035962A patent/UY35962A/es not_active Application Discontinuation
- 2015-01-22 TW TW104102153A patent/TW201605446A/zh unknown
-
2016
- 2016-07-04 IL IL246598A patent/IL246598B/en active IP Right Grant
- 2016-07-22 CL CL2016001874A patent/CL2016001874A1/es unknown
-
2018
- 2018-08-28 US US16/115,105 patent/US20190209542A1/en not_active Abandoned
-
2019
- 2019-09-30 JP JP2019179329A patent/JP7266298B2/ja active Active
-
2021
- 2021-01-28 IL IL280485A patent/IL280485B2/en unknown
-
2023
- 2023-10-23 US US18/491,871 patent/US20240041855A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY35962A (es) | Formulaciones de liberación modificada de pridopidina | |
| MX2024004439A (es) | Agentes terapeuticos para enfermedades neurodegenerativas | |
| MX2017010982A (es) | Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer. | |
| CO2017013293A2 (es) | Formulaciones farmacéuticas que comprenden tenofovir y emtricitabina | |
| WO2014205229A8 (en) | Use of high dose pridopidine for treating huntington's disease | |
| HK1258570A1 (zh) | 使用dna损伤剂及atr抑制剂的组合治疗癌症的方法 | |
| MX380798B (es) | Profármacos de alvocidib que tienen una biodisponibilidad aumentada. | |
| BR112017028140A2 (pt) | formulações farmacêuticas | |
| CR20180253A (es) | Composiciones terapéuticas para el tratamiento del virus de unmunodeficiencia humana | |
| MX368903B (es) | Compuestos terapéuticos y sus usos en el tratamiento de enfermedades proliferativas. | |
| MX2014006762A (es) | Metodos para el tratamiento de desordenes cardiovasculares. | |
| MA39765A (fr) | Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation | |
| WO2012100043A3 (en) | Controlled release oral pharmaceutical dosage forms comprising mgbg | |
| UA115250C2 (uk) | Фармацевтичні комбінації | |
| AR099299A1 (es) | Inhibidor de la proteína de transferencia de éster de colesterilo (cetp) y composiciones farmacéuticas que comprenden dicho inhibidor para uso en el tratamiento o prevención de enfermedades cardiovasculares | |
| CR20170125A (es) | Composición farmacéutica sólica que comprende amlodipina y losartán | |
| MX374938B (es) | Un método para el tratamiento de trastornos del movimiento con befiradol. | |
| PH12014500684A1 (en) | Treatment of rhinitis | |
| CL2017000026A1 (es) | Formas de dosificación farmacéutica | |
| TW201613600A (en) | Piperazinyl derivative reduces HFD-induced accumulation of fat in the liver, therapeutically | |
| AR109209A1 (es) | Composición farmacéutica para prevención o tratamiento de enfermedades neurodegenerativas | |
| CR20170601A (es) | Formulaciones farmaceuticas que comprenden tenofovir y emtricitabina | |
| IN2014CH00149A (OSRAM) | ||
| UA95834U (uk) | Спосіб лікування гострого ішемічного інсульту | |
| MX2016010919A (es) | 4-bencilsulfonil-2-butenonitrilo. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 109 | Application deemed to be withdrawn |
Effective date: 20220610 |